Gainers

• Adlai Nortye (NASDAQ:ANL) shares moved upwards by 16.9% to $15.5 during Thursday's pre-market session. The market value of their outstanding shares is at $703.2 million.
• Aligos Therapeutics (NASDAQ:ALGS) shares moved upwards by 15.22% to $8.55. The company's market cap stands at $45.9 million.
• CareDx (NASDAQ:CDNA) stock increased by 10.13% to $19.35. The company's market cap stands at $935.1 million.
• Hims & Hers Health (NYSE:HIMS) shares moved upwards by 9.67% to $26.64. The market value of their outstanding shares is at $5.5 billion.
• Vivani Medical (NASDAQ:VANI) shares increased by 9.64% to $1.25. The market value of their outstanding shares is at $96.4 million.
• American Shared Hospital (AMEX:AMS) stock moved upwards by 9.3% to $1.41. The company's market cap stands at $8.4 million.

Losers

• QuidelOrtho (NASDAQ:QDEL) stock declined by 16.2% to $14.65 during Thursday's pre-market session. The market value of their outstanding shares is at $1.1 billion.
• Inotiv (NASDAQ:NOTV) stock fell 15.3% to $0.33. The market value of their outstanding shares is at $13.4 million.
• Wellgistics Health (NASDAQ:WGRX) stock declined by 14.98% to $0.13. The market value of their outstanding shares is at $18.7 million.
• NewGenIvf Group (NASDAQ:NIVF) shares declined by 14.29% to $2.04. The market value of their outstanding shares is at $1.3 million.
• MeiraGTx Holdings (NASDAQ:MGTX) stock fell 12.89% to $9.8. The company's market cap stands at $916.2 million.
• Vivos Therapeutics (NASDAQ:VVOS) stock declined by 11.6% to $1.3. The market value of their outstanding shares is at $17.3 million. As per the news, the Q4 earnings report came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.